Academic Journal
Baseline B-Type Natriuretic Peptide and Clinical Outcomes Following Transcatheter Tricuspid Valve Replacement.
| Title: | Baseline B-Type Natriuretic Peptide and Clinical Outcomes Following Transcatheter Tricuspid Valve Replacement. |
|---|---|
| Authors: | Andrews T; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Coombe V; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., McBride P; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Gonzalez PE; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Lee J; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Dawdy J; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Zweig B; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Frisoli TM; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Villablanca P; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Golwala H; Division of Cardiology, OHSU Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon., Amoroso NS; Division of Cardiology, MUSC Health, Medical University of South Carolina, Charleston, South Carolina., Zahr F; Division of Cardiology, OHSU Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon., O'Neill BP; Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan. Electronic address: boneil3@hfhs.org. |
| Source: | The American journal of cardiology [Am J Cardiol] 2026 Aug 01; Vol. 272, pp. 9-11. Date of Electronic Publication: 2026 May 09. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Excerpta Medica Country of Publication: United States NLM ID: 0207277 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1913 (Electronic) Linking ISSN: 00029149 NLM ISO Abbreviation: Am J Cardiol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: New York, NY : Excerpta Medica |
| MeSH Terms: | Natriuretic Peptide, Brain*/blood , Tricuspid Valve Insufficiency*/surgery , Tricuspid Valve Insufficiency*/blood , Tricuspid Valve Insufficiency*/mortality , Heart Valve Prosthesis Implantation*/methods , Cardiac Catheterization*/methods , Tricuspid Valve*/surgery, Biomarkers/blood ; Humans ; Female ; Male ; Aged ; Treatment Outcome ; Aged, 80 and over ; Severity of Illness Index ; Follow-Up Studies ; Retrospective Studies |
| Abstract: | Transcatheter tricuspid valve replacement (TTVR) has emerged as a nonsurgical approach for patients with severe tricuspid regurgitation. However, clinical variables which may impact the overall patient response to TTVR remain elusive. B-type natriuretic peptide (BNP) may reflect disease severity, which in turn may help predict response to TTVR and identify patients at increased risk of adverse outcomes. We evaluated the association between baseline BNP and clinical outcomes (all-cause hospitalization or death) and Kansas City Cardiomyopathy Questionnaire at 30-days and 1-year among 148 patients undergoing TTVR. BNP was analyzed as both a continuous variable and stratified by tertiles. Baseline BNP tertile was not associated with improvement in health status measured by change in Kansas City Cardiomyopathy Questionnaire score at 30-days (p = 0.48) or 1-year (p = 0.57). Sixteen patients (10.8%) experienced a 30-day event and 34 (23%) experienced a 1-year event. Baseline BNP was higher among patients experiencing 1-year events compared with those without events (median 668 vs 375 pg/ml, p = 0.004). One-year event rates increased stepwise across BNP tertiles (10.2%, 22.5%, and 36.0%; p = 0.0095) at 1-year. In a multivariable Cox regression analysis adjusting for age, body mass index, and serum creatinine, higher baseline BNP was independently associated with the composite endpoint of death or rehospitalization (hazard ratio 1.74, 95% confidence interval 1.15 to 2.64, p = 0.00912). Higher baseline BNP was associated with increased risk of adverse clinical outcomes following TTVR but was not associated with improvement in patient-reported health status. BNP may serve as a marker of disease severity and risk stratification in patients undergoing TTVR. (Copyright © 2026 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tiberio Frisoli reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory. Tiberio Frisoli reports a relationship with Abbott that includes: consulting or advisory. Tiberio Frisoli reports a relationship with Boston Scientific Corporation that includes: consulting or advisory. Tiberio Frisoli reports a relationship with Medtronic Inc that includes: consulting or advisory. Brian P. O’Neill reports a relationship with Abbott that includes: consulting or advisory. Brian P. O’Neill reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory. Brian P. O’Neill reports a relationship with Medtronic Inc that includes: consulting or advisory. Brian P. O’Neill reports a relationship with Edwards Lifesciences Corporation that includes: funding grants. Pedro Villablanca reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory. Pedro Villablanca reports a relationship with Teleflex Medical Incorporated that includes: consulting or advisory. Harsh Golwala reports a relationship with Boston Scientific Corporation that includes: consulting or advisory. Harsh Golwala reports a relationship with Medtronic Inc that includes: consulting or advisory. Nicholas S. Amoroso reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory. Nicholas S. Amoroso reports a relationship with Abbott Laboratories Inc that includes: consulting or advisory. Nicholas S. Amoroso reports a relationship with Boston Scientific Corporation that includes: consulting or advisory. Nicholas S. Amoroso reports a relationship with Nininger Medical that includes: consulting or advisory. Nicholas S. Amoroso reports a relationship with JenaValve Technology Inc that includes: consulting or advisory. Nicholas S. Amoroso reports a relationship with VDyne Medical that includes: consulting or advisory. Firas Zahr reports a relationship with Abbott that includes: consulting or advisory. Firas Zahr reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory. Firas Zahr reports a relationship with General Electric Company that includes: consulting or advisory. Firas Zahr reports a relationship with Medtronic Inc that includes: consulting or advisory. Firas Zahr reports a relationship with Philips North America LLC that includes: consulting or advisory. Firas Zahr reports a relationship with Cardiovascular Research Foundation that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: B-type natriuretic peptide; biomarkers; risk stratification; transcatheter tricuspid valve replacement; tricuspid regurgitation |
| Substance Nomenclature: | 114471-18-0 (Natriuretic Peptide, Brain) 0 (Biomarkers) |
| Entry Date(s): | Date Created: 20260511 Date Completed: 20260710 Latest Revision: 20260710 |
| Update Code: | 20260711 |
| DOI: | 10.1016/j.amjcard.2026.05.005 |
| PMID: | 42114631 |
| Database: | MEDLINE |
| ISSN: | 1879-1913 |
|---|---|
| DOI: | 10.1016/j.amjcard.2026.05.005 |